1632. A cohort study on the outcome of multidrug-resistant tuberculosis among newly diagnosed cases
Session: Poster Abstract Session: Mycobacterial Infections
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • poster-ʦ.png (391.1 kB)
  • Background: The increasing incidence of multidrug resistant tuberculosis (MDR-TB)  is a major concern for TB control programs worldwide. To investigate the characteristics, treatment outcomes of first treated MDR-TB.

    Methods: We retrospectively analyzed  TB Patients with culture-proven MDR-TB and HIV-negative in Shanghai pulmonary hospital  in China,from January 2006 to January 2009.

    Results: There are 408 cases divided into first treated group and retreatment group.The sputum conversion rates,the lesions absorption rate and the cavity closure or reduced rate of the first treated MDR-TB group were significantly higher than that of the retreatmentt group. The adverse effect rate was not significantly different between two groups(χ2=0.434,P>0.05).Among 89 cases of new cases,66 cases were cured (74.15%), 8 cases were completion of treatment (8.99%), 7 cases were treatment failure (7.87%), 3 cases died (3.37%), 5 cases was lost to follow-up (5.61%). Among 319 cases of retreatment MDR-TB group, 134 cases were cured (42.01%);31 cases were completion of treatment (9.72%);116 cases were treatment failure (36.36%);12 patients died (3.76%);26 cases were lost to follow-up (8.15%). The cure rate of the first treated MDR-TB group was significantly higher than retreated group (χ2=28.783,P<0.001). The factors may be the course of disease, the range of lesions and cavity, the general nutritional status, complications, and the extent of drug-resistant .

    Conclusion:  The clinical curative effect and outcome of first treated MDR-TB group were significantly better than those of retreatment MDR-TB group Therefore,To strengthen surveillance of the drug resistance, to detect MDR-TB as early as possible and to modify treatment regimen timely can improve the cure rate.

    Xiaohui Hao, Shenjie Tang and Lan Yao, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China


    X. Hao, None

    S. Tang, None

    L. Yao, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.